Description: Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Home Page: cantargia.com
Ideon Gateway
Lund,
223 63
Sweden
Phone:
46 4 62 75 62 60
Officers
| Name | Title |
|---|---|
| Mr. Goran Forsberg | Chief Executive Officer |
| Mr. Thoas Fioretos M.D., Ph.D. | Founder & Scientific Advisor |
| Mr. Marcus Järås | Founder & Scientific Advisor |
| Mr. Kjell Sjöström | Founder |
| Mr. Patrik Renblad | Chief Financial Officer |
| Dr. David Liberg | Chief Scientific Officer |
| Nina Valkama | Executive Assistant of Administration & Finance |
| Dr. Dominique Tersago | Chief Medical Officer |
| Mr. Antonius Berkien | Chief Business Officer |
| Johanna Christensen | Financial Controller |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 2.8596 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.4093 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |